Oncology Accelerated Approval Re-Reviews: US FDA’s Pazdur Is Not Backing Down
Executive Summary
How has FDA suddenly been able to enforce accelerated approval commitments in oncology? The agency’s Richard Pazdur reflects on lessons from 2021 – and promises more re-reviews to come.
You may also be interested in...
US FDA Advisory Committees: Flipping FDAAA Mandate On Its Head
FDA’s use of advisory committees is at a historic low – as are the prospects of sponsors getting a positive outcome. Is it COVID? Or a more fundamental shift in how FDA uses its panels?
Keeping Track: US FDA Clears On Target’s Cytalux, VBI’s PreHevbrio; Keytruda Grows In Adjuvant Melanoma
The latest FDA approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA Cancels Panel Review Of Two ‘Delinquent’ Cancer Drug Accelerated Approvals
Confirmatory trial for Secura Bio’s Farydak has been delayed for several years, while the study for Acrotech’s Marqibo was terminated early; a 2 December advisory committee meeting to consider the drugs’ fate was cancelled, which could mean the sponsors reached new study agreements with the FDA or plan to withdraw the drugs.